Clearmind Medicine Inc CMND shares are surging Wednesday after the company said it completed a Type A meeting with the U.S. Food and Drug Administration.
What Happened: Clearmind has completed a Type A meeting with the FDA regarding the company’s clinical trial of its CMND-100 compound for the treatment of Alcohol Use Disorder using psychedelic- based therapy.
The active ingredient in CMND-100 is MEAI, a novel psychoactive molecule that has been reported to reduce desires to consume alcoholic drinks while exerting a euphoric alcohol-like experience.
“We’re pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.
“The meeting was informative and productive, and we’re eager to advance the U.S. regulatory process and potentially bring a new hope for millions suffering from AUD by providing an innovative approach to overcome the challenges associated with the current available treatments to date.”
Clearmind is a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems.
See Also: Why Connected Supply Chain Software Platform E2open Shares Are Higher Today
CMND Price Action: Clearmind shares were up 64.3% at $3.38 at the time of publication, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
